JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with relapsed or refractory Hodgkin Lymphoma (HL). - JeRiCHO (JAK-inhbition in recurrent classical Hodgkin Lymphoma)

niversity of cologne0 个研究点目标入组 14 人开始时间: 2015年7月10日最近更新: 2020年7月20日

适应症

试验速览

暂无简介。

•Patients with relapsed or refractory HL after any polychemotherapy regimen including HDCT and ASCT who are not eligible for (another) HDCT and ASCT; age: 18 to 99 years; ECOG = 2, no major organ dysfunction (except HL related), written informed consent; Absolute Neutrophil Count (ANC) = 1.0 x 109/L, platelets = 100 x 109/L; Total bilirubin = 2 x ULN (if >2 x ULN direct bilirubin is required and should be =1.5 x ULN); ASAT = 3 x ULN (= 5 x ULN if liver involvement is present); serum creatinine = 2 x ULN; =2 weeks since last tumor therapy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 37
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 37

•Patients who have a history of another primary malignancy = 2 years; Female patients who are pregnant or breast feeding; Patients who are using other investigational agents or who had received investigational drugs = 4 weeks prior to study drug start; Patients with a known history of HIV seropositivity, chronic active hepatitis

发起方

niversity of cologne